SCHEMBL354525

SCHEMBL354525

O=C(CCCCCn1c2ccc(Br)cc2c(=O)c2cc(Br)ccc21)ON1C(=O)CCC1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.40
HDAC1 Q13547 5/20 0.38
HDAC6 Q9UBN7 5/20 0.38
HDAC3 O15379 2/20 0.38
HDAC4 P56524 2/20 0.38
HDAC7 Q8WUI4 2/20 0.38
HDAC2 Q92769 2/20 0.38
HDAC10 Q969S8 2/20 0.38
HDAC11 Q96DB2 2/20 0.38
HDAC8 Q9BY41 2/20 0.38
HDAC9 Q9UKV0 2/20 0.38
HDAC5 Q9UQL6 2/20 0.38
CNR2 P34972 4/20 0.37
SIGMAR1 Q99720 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
GSK3B P49841 2/20 0.36
CNR1 P21554 2/20 0.36
ALDH1A1 P00352 1/20 0.35
FABP4 P15090 1/20 0.35
FABP5 Q01469 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL353722 0.95 HDAC1 (0.46) HDAC1HDAC6HDAC3HDAC4HDAC7
SCHEMBL353790 0.84 HDAC1 (0.51) HDAC1HDAC6HDAC3HDAC4HDAC7
SCHEMBL353749 0.81 SMN1; SMN2 (0.49) CNR2SMN1; SMN2GSK3BALDH1A1LMNA
SCHEMBL357128 0.80 HDAC1 (0.41) HDAC1HDAC6HDAC3HDAC4HDAC7
SCHEMBL355687 0.80 FABP4 (0.56) HDAC1HDAC6HDAC3HDAC4HDAC7
SCHEMBL353757 0.78 NPC1 (0.49) HDAC1HDAC6HDAC3HDAC4HDAC7
SCHEMBL951235 0.78 MEN1 (0.35) CNR2SMN1; SMN2ALDH1A1LMNA
SCHEMBL1415451 0.77 FABP4 (0.54) HDAC1HDAC6HDAC3HDAC4HDAC7
SCHEMBL354741 0.76 TNF (0.53) HDAC1HDAC6HDAC3HDAC4HDAC7
SCHEMBL1415560 0.76 TERT (0.32) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120015373-A1 ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS GE HEALTHCARE UK LIMITED (GB) 2012-01-19 US disclosed
US-20120015373-A1 ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS GE HEALTHCARE UK LIMITED (GB) 2012-01-19 US disclosed
US-20120015373-A1 ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS GE HEALTHCARE UK LIMITED (GB) 2012-01-19 US disclosed
US-8034558-B2 Incubating dye of given formula with biological material, measuring fluorescence lifetime; lectins/glycoproteins, biotin/streptavidin, DNA/RNA GE HEALTHCARE UK LIMITED (GB) 2011-10-11 US disclosed
US-8034558-B2 Incubating dye of given formula with biological material, measuring fluorescence lifetime; lectins/glycoproteins, biotin/streptavidin, DNA/RNA GE HEALTHCARE UK LIMITED (GB) 2011-10-11 US disclosed
US-8034558-B2 Incubating dye of given formula with biological material, measuring fluorescence lifetime; lectins/glycoproteins, biotin/streptavidin, DNA/RNA GE HEALTHCARE UK LIMITED (GB) 2011-10-11 US disclosed
US-20080139788-A1 ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS GE HEALTHCARE UK LIMITED (GB) 2008-06-12 US disclosed
US-20080139788-A1 ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS GE HEALTHCARE UK LIMITED (GB) 2008-06-12 US disclosed
US-20080139788-A1 ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS GE HEALTHCARE UK LIMITED (GB) 2008-06-12 US disclosed
US-20040191792-A1 Acridone derivatives as labels for fluorescence detection of target materials GE HEALTHCARE UK LIMITED (GB) 2004-09-30 US disclosed
EP-1392776-A2 ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS Amersham Biosciences UK Limited (GB) 2004-03-03 EP disclosed
WO-2002099424-A2 ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS AMERSHAM BIOSCIENCES UK LIMITED (GB) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139788-A1 ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS ACR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ARSA HSD17B10 2718/4885HDAC1 655/4885HDAC6 1327/4885
US-20040191792-A1 Acridone derivatives as labels for fluorescence detection of target materials ACR, ARSA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 HSD17B10 2092/4885HDAC1 2453/4885HDAC6 1983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.